---
title: Reduce tremor and improve gait
nct_id: NCT07384442
phase: NA
status: RECRUITING
sponsor: YangPan
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07384442"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07384442"
last_fetched: "2026-05-10T14:06:25.816Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce tremor and improve gait

**Goal (in five words):** Reduce tremor and improve gait

**Official Title:** Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's Disease Patients

**Trial ID:** [NCT07384442](https://clinicaltrials.gov/study/NCT07384442)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** YangPan
- **Target Enrollment:** 50 participants
- **Start Date:** 2026-03-19
- **Completion Date:** 2026-12-31
- **Conditions:** Parkinson's Disease, Movement Disorders
- **Interventions:** Sham Temporal Interference Stimulation, Real Temporal Interference Stimulation
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to reduce tremor and improve walking and balance by calming abnormal activity in the cerebellar nuclei that can worsen those problems in Parkinson's. The team uses targeted temporal interference stimulation, a noninvasive electrical method that sends two high-frequency currents through the skull so they interfere and create a low-frequency signal deep in the cerebellar nuclei, modulating their output to try to lessen tremor and improve gait while participants continue their usual levodopa rather than replace it. They are looking for people 50 or older with idiopathic Parkinson's for at least two years who have tremor and gait disturbance, respond to levodopa, have had stable medications for four weeks, can walk independently for five minutes, and do not have major cognitive impairment, recent neuromodulation, or metal implants like DBS or a pacemaker.

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* 1.Aged 50 years or older;
* 2.Confirmed diagnosis of idiopathic Parkinson's disease (IPD) according to the 2015 MDS diagnostic criteria, with tremor and gait disturbance;
* 3.Disease duration ≥2 years after diagnosis, stable condition, and ability to cooperate with study assessment and intervention;
* 4.Stable medication dosage for at least 4 weeks prior to the trial;
* 5.Good response to Levodopa therapy;
* 6.Capable of independent walking (without assistive devices) for at least 5 minutes and able to complete gait testing independently.
* 7.Signed informed consent form, with the participant or their legal guardian able to understand and willing to participate in this study.

Exclusion Criteria:

* 1.History or confirmed diagnosis of severe mental disorders, such as depression, anxiety disorders, schizophrenia spectrum disorders, and bipolar disorder;
* 2.The subject has clinically defined neurological conditions (assessed through self-report), including but not limited to: any disease potentially associated with increased intracranial pressure, space-occupying lesions, stroke history, transient ischemic attack (TIA) within the past two years, cerebral aneurysm, dementia, multiple sclerosis;
* 3.Severe cognitive impairment, Mini-Mental State Examination (MMSE) score \<22, or inability to independently complete questionnaires;
* 4.Inability to read or understand Chinese;
* 5.Use of other neuromodulatory therapies within the past 3 months;
* 6.Presence of musculoskeletal or orthopedic conditions (e.g., severe arthritis, recent fractures) that significantly interfere with gait or balance;
* 7.Presence of metal implants (e.g., Deep Brain Stimulation, cardiac pacemakers) or contraindications for MRI/TIS;
* 8.Current use of medications that affect dopamine levels (e.g., antipsychotics);
* 9.Severe cardiovascular disease or other unstable medical conditions that preclude physical exertion or study participation;
```

## Locations (1)

- Zhongnan hospital, Wuhan, Hubei, China _(30.5833, 114.2667)_
  - Yang Pan, Chief Physician — (CONTACT) — 0258-2263671 — neuro_panyang@163.com

## Central Contacts

- Yang Pan — (CONTACT) — +8613952098253 — panyang.zn@whu.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07384442*  
*HTML version: https://parkinsonspathways.com/trial/NCT07384442*  
*Source data: https://clinicaltrials.gov/study/NCT07384442*